Compare · CURX vs NVO
CURX vs NVO
Side-by-side comparison of Curanex Pharmaceuticals Inc (CURX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CURX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $186.77B, about 20533.7x CURX ($9.1M).
- NVO has been more active in the news (6 items in the past 4 weeks vs 2 for CURX).
- NVO has more recent analyst coverage (25 ratings vs 0 for CURX).
- Company
- Curanex Pharmaceuticals Inc
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $9.1M
- $186.77B
- 1M return
- -
- +12.36%
- 1Y return
- -
- -12.97%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 6
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CURX
- SEC Form S-8 filed by Curanex Pharmaceuticals Inc
- SEC Form 8-K filed by Curanex Pharmaceuticals Inc
- Curanex Pharmaceuticals Inc filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 10-Q filed by Curanex Pharmaceuticals Inc
- SEC Form S-8 filed by Curanex Pharmaceuticals Inc
- SEC Form DEF 14C filed by Curanex Pharmaceuticals Inc
- SEC Form PRE 14C filed by Curanex Pharmaceuticals Inc
- Curanex Pharmaceuticals Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Curanex Pharmaceuticals Inc
- Curanex Pharmaceuticals Inc filed SEC Form 8-K: Other Events
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S